This is a small insider buy from the CSO, not a material signal. Monitor for upcoming Phase 3 trial initiation for urcosimod in NCP, which is the primary catalyst. The 20-F annual report filed 8 days ago provides the full financial context for the fiscal year ended March 31, 2026.
Price Chart
Executive Summary
OKYO Pharma's Chief Scientific Officer Raj Patil purchased 3,363 ordinary shares at $1.49 per share on the open market, increasing his total holding to 20,030 shares. This is a small insider buy ($5,011 total) from a single executive at a $55M market cap clinical-stage biotech, providing a modest signal of alignment but no material change to the company's fundamentals or pipeline outlook.
Key Facts
- CSO Raj Patil purchased 3,363 ordinary shares at $1.49 per share on Nasdaq
- Purchase increases Patil's total holding to 20,030 ordinary shares
- Total purchase value is approximately $5,011
- OKYO is a clinical-stage biopharma developing urcosimod for neuropathic corneal pain (NCP)
- Company plans to initiate a global Phase 3 pivotal trial in H2 2026 enrolling ~111 patients
Financial Impact
CSO purchased $5,011 worth of shares at $1.49/share; no financial data or guidance provided in this filing
Risk Factors
- Insider buy is very small ($5K) and from a single executive, not a cluster of buys
- Clinical-stage biotech with no approved products — pipeline risk remains high
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-034927 |
| Exhibit: ex99-1.htm | 0001493152-26-034927 |
| Document: 0001493152-26-034927-index-headers.html | 0001493152-26-034927 |
| Document: 0001493152-26-034927-index.html | 0001493152-26-034927 |
| Document: 0001493152-26-034927.txt | 0001493152-26-034927 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers